Σφακιανάκης Αλέξανδρος
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5 Άγιος Νικόλαος
Κρήτη 72100
00302841026182
00306932607174
alsfakia@gmail.com

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Πέμπτη 10 Αυγούστου 2017

When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council

Publication date: Available online 10 August 2017
Source:Journal of the American Academy of Dermatology
Author(s): Eric L. Simpson, Marjolein Bruin-Weller, Carsten Flohr, Michael R. Ardern-Jones, Sebastien Barbarot, Mette Deleuran, Thomas Bieber, Christian Vestergaard, Sara J. Brown, Michael J. Cork, Aaron M. Drucker, Lawrence F. Eichenfield, Regina Foelster-Holst, Emma Guttman-Yassky, Audrey Nosbaum, Nick J. Reynolds, Jonathan I. Silverberg, Jochen Schmitt, Marieke M.B. Seyger, Phyllis I. Spuls, Jean-Francois Stalder, John C. Su, Roberto Takaoka, Claudia Traidl-Hoffmann, Jacob P. Thyssen, Jorien van der Schaft, Andreas Wollenberg, Alan D. Irvine, Amy S. Paller
BackgroundAlthough most patients with atopic dermatitis (AD) are effectively managed with topical medication, a significant minority require systemic therapy. Guidelines for decision making about advancement to systemic therapy are lacking.ObjectiveTo guide those considering use of systemic therapy in AD and provide a framework for evaluation before making this therapeutic decision with the patient.MethodsA subgroup of the International Eczema Council determined aspects to consider before prescribing systemic therapy. Topics were assigned to expert reviewers who performed a topic-specific literature review, referred to guidelines when available, and provided interpretation and expert opinion.ResultsWe recommend a systematic and holistic approach to assess patients with severe signs and symptoms of AD and impact on quality of life before systemic therapy. Steps taken before commencing systemic therapy include considering alternate or concomitant diagnoses, avoiding trigger factors, optimizing topical therapy, ensuring adequate patient/caregiver education, treating coexistent infection, assessing the impact on quality of life, and considering phototherapy.LimitationsOur work is a consensus statement, not a systematic review.ConclusionThe decision to start systemic medication should include assessment of severity and quality of life while considering the individual's general health status, psychologic needs, and personal attitudes toward systemic therapies.



http://ift.tt/2vUk4w5

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου